中国当代医药
中國噹代醫藥
중국당대의약
China Modern Medicine
2015年
27期
88-90,93
,共4页
章国仁%王爱华%方幼荣%江世亭
章國仁%王愛華%方幼榮%江世亭
장국인%왕애화%방유영%강세정
肥胖型2型糖尿病%利拉鲁肽%给药剂量
肥胖型2型糖尿病%利拉魯肽%給藥劑量
비반형2형당뇨병%리랍로태%급약제량
Obese type 2 diabetes%Liraglutide%Dosage
目的:探讨不同剂量利拉鲁肽治疗肥胖型2型糖尿病的临床疗效。方法选取我院2013年5月~2015年5月收治的88例肥胖型2型糖尿病患者作为研究对象,按随机数字表法分为A、B两组(每组44例),两组患者均应用利拉鲁肽进行治疗,A组的单次给药剂量为1.2 mg,B组为1.8 mg,比较两组患者的治疗效果。结果两组患者治疗前的各项糖代谢、脂代谢、CRP及心血管指标比较,差异无统计学意义(P>0.05)。治疗后,两组患者的FPG、2 hPG、BMI、TG、TC、LDL-C、CRP及各项心血管指标均较治疗前显著降低(P<0.05),组间比较差异无统计学意义(P>0.05)。两组的一般低血糖及局部瘙痒、硬结发生率比较差异无统计学意义(P>0.05),A组的一过性腹泻、一过性胃肠道反应发生率均显著低于B组(P<0.05)。结论利拉鲁肽治疗肥胖型2型糖尿病具有良好的效果,单次给药剂量1.2 mg的治疗效果与1.8 mg相当,低剂量用药安全性更高。
目的:探討不同劑量利拉魯肽治療肥胖型2型糖尿病的臨床療效。方法選取我院2013年5月~2015年5月收治的88例肥胖型2型糖尿病患者作為研究對象,按隨機數字錶法分為A、B兩組(每組44例),兩組患者均應用利拉魯肽進行治療,A組的單次給藥劑量為1.2 mg,B組為1.8 mg,比較兩組患者的治療效果。結果兩組患者治療前的各項糖代謝、脂代謝、CRP及心血管指標比較,差異無統計學意義(P>0.05)。治療後,兩組患者的FPG、2 hPG、BMI、TG、TC、LDL-C、CRP及各項心血管指標均較治療前顯著降低(P<0.05),組間比較差異無統計學意義(P>0.05)。兩組的一般低血糖及跼部瘙癢、硬結髮生率比較差異無統計學意義(P>0.05),A組的一過性腹瀉、一過性胃腸道反應髮生率均顯著低于B組(P<0.05)。結論利拉魯肽治療肥胖型2型糖尿病具有良好的效果,單次給藥劑量1.2 mg的治療效果與1.8 mg相噹,低劑量用藥安全性更高。
목적:탐토불동제량리랍로태치료비반형2형당뇨병적림상료효。방법선취아원2013년5월~2015년5월수치적88례비반형2형당뇨병환자작위연구대상,안수궤수자표법분위A、B량조(매조44례),량조환자균응용리랍로태진행치료,A조적단차급약제량위1.2 mg,B조위1.8 mg,비교량조환자적치료효과。결과량조환자치료전적각항당대사、지대사、CRP급심혈관지표비교,차이무통계학의의(P>0.05)。치료후,량조환자적FPG、2 hPG、BMI、TG、TC、LDL-C、CRP급각항심혈관지표균교치료전현저강저(P<0.05),조간비교차이무통계학의의(P>0.05)。량조적일반저혈당급국부소양、경결발생솔비교차이무통계학의의(P>0.05),A조적일과성복사、일과성위장도반응발생솔균현저저우B조(P<0.05)。결론리랍로태치료비반형2형당뇨병구유량호적효과,단차급약제량1.2 mg적치료효과여1.8 mg상당,저제량용약안전성경고。
Objective To investigate the clinical efficacy of different doses of liraglutide treat with obese type 2 dia-betes. Methods 88 patients with obesity type 2 diabetes from May 2013 to May 2015 in our hospital were divided into group A and group B by the random number table (n=44 cases).All patients were treated with liraglutide,group A single dosage was 1.2 mg,group B was 1.8 mg,therapeutic effect between two groups was compared. Results The glucose metabolism,lipid metabolism,CRP and cardiovascular indicators of group A compared with group B were no significant difference (P>0.05).After treatment,the FPG,2 hPG,BMI,TG,TC,LDL-C,CRP and cardiovascular indices between two groups was significantly lower than before treatment respectively,with statistical differenc (P<0.05);General hypo-glycemia,local itching and induration incidence between two groups was not statistically significant (P>0.05),but tran-sient diarrhea,transient gastrointestinal reactions of group A were significantly lower than group B(P<0.05). Conclusion Liraglutide treatment of obesity type 2 diabetes has a good effect,a single dose of 1.2 mg can provide the same effect with 1.8 mg,but low doses of medication is more security.